Donanemab( —— )

Catalog No. M36837 CAS No. 1931944-80-7

Donanemab (LY3002813) is a humanized IgG1 monoclonal antibody that targets a pyroglutamate amyloid beta (Aβ) epitope at the N-terminus, showing potential for early Alzheimer's disease research .

Purity : >98% (HPLC)

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Size	Price / USD	Stock	Quantity
5MG	560	In Stock
10MG	911	In Stock
25MG	1349	In Stock
50MG	1786	In Stock
100MG	2409	In Stock
200MG	Get Quote	In Stock
500MG	Get Quote	In Stock
1G	Get Quote	In Stock

Get Quotation Bulk Inquiry Add to Cart

Biological Information

Product Name

Donanemab
Note

Research use only, not for human use.
Brief Description

Donanemab (LY3002813) is a humanized IgG1 monoclonal antibody that targets a pyroglutamate amyloid beta (Aβ) epitope at the N-terminus, showing potential for early Alzheimer's disease research .
Description

Donanemab (LY3002813) is a humanized IgG1 monoclonal antibody directed at an N‐terminal pyroglutamate amyloid beta (Aβ) epitope. Donanemab has the potential for early Alzheimer's disease research.
In Vitro

——
In Vivo

——
Synonyms

——
Pathway

Others
Target

Other Targets
Recptor

Microtubule Associated | Beta Amyloid
Research Area

——
Indication

——

Chemical Information

CAS Number

1931944-80-7
Formula Weight
Molecular Formula

——
Purity

>98% (HPLC)
Solubility

——
SMILES

——
Chemical Name

——

Shipping & Storage Information

Storage

(-20℃)
Shipping

With Ice Pack
Stability

≥ 2 years

Reference

1. Stephen Loucian Lowe, et al. Donanemab (LY3002813) dose-escalation study in Alzheimer's disease. Alzheimers Dement (N Y). 2021 Feb 14;7(1):e12112.?

Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog

Product			Quantity Required*
Name *			E-mail Address *
Organization *			Phone Number
Remarks